亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台,协助业界发掘知识产权贸易商机,并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权,或是制造商需要购买技术以提高操作效能,又或是知识产权配套服务供应商,你将会从本网站发掘到有用的知识产权贸易资讯。

Combination Therapy For The Treatment Of Influenza

总结
Compositions And Methods For Treating One Or More Symptoms Of Influenza, Preferably Influenza Due To Infection With Influenza A (H5n1) Are Provided. It Has Been Discovered That Administration Of A Combination Of A Neuraminidase Inhibitor With Two Immunomodulators Increases Survivability In Subjects 24, 48, Or Even 72 Hours Post Infection Compared To Administration Of The Neuraminidase Inhibitor Alone. A Preferred Neuraminidase Inhibitor Is Zanamivir. Preferred Immunomodulators Include, But Are Not Limited To Celecoxib And Mesalazine. Another Embodiment Provides A Method For Treating Influenza, Preferably, Influenza Due To Infection With Avian Influenza A (H5n1) By Administering To Subject Infected With The Influenza Virus, An Effective Amount Of A Neuraminidase Inhibitor To Inhibit Or Reduce Budding Of The Influenza Virus From Infected Cells Of The Subject, And An Effective Amount Of At Least Two Immunomodulators Effective To Reduce Or Inhibit One Or More Symptoms Of Inflammation In The Subject.
附加资料
Patent Number: CN102036658A
Application Number: CN200980119926A
Inventor: YUAN, Guo-yong | ZHENG, Bo-jian
Priority Date: 23 May 2008
Priority Number: CN102036658A
Application Date: 7 May 2009
Publication Date: 27 Apr 2011
IPC Current: A61K0031155 | A61K0031196 | A61K0031415 | A61K0031606 | A61P003116
Assignee Applicant: The University of Hong Kong
Title: Combination therapy for the treatment of influenza
Usefulness: Combination therapy for the treatment of influenza
Summary: For treating symptoms of influenza such as influenza A (H5N1); for inhibiting or reducing budding of influenza virus from infected cells, and reducing at least one symptoms of inflammation of the subject (claimed).
Novelty: Pharmaceutical composition useful for treating influenza A, comprises neuraminidase inhibitor to inhibit budding of influenza virus from infected cells; and at least two immunomodulators effective to reduce symptoms of inflammation
主要类别
生物医学
细分类别
医药成分
申请号码
CN200980119926A
国家/地区
香港

欲了解更多信息,请点击 这里
移动设备